Synopsis
When PE firm KKR took control of JB Pharma in 2020, it was struggling for growth. Competitors had cornered the four legacy brands on which the company relied. Then, Nikhil Chopra, a seasoned hand from Cipla, took over. JB Pharma’s subsequent turnaround is a tale of calculated risks, deft moves, and rebuilding. But the going gets tough from here.
Nikhil Chopra can feel the pulse of the Indian pharmaceutical market. It comes naturally for someone who has worked at Cipla for over 24 years, rising through the ranks, from his humble beginnings as a medical representative in Ahmedabad in 1996 to taking full charge of its India operations in 2003. A consummate marketing professional, Chopra prides in having kept Cipla among India’s three leading drugmakers, after Sun Pharma and Abbott, amid
BY
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Minimal Ads
Comment & Engage with ET Prime community 
Exclusive invites to Virtual Events with Industry Leaders 
A trusted team of Journalists & Analysts who can best filter signal from noise 
Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-
